Top

Osteoporosis International

Published in:

01-11-2007 | Review

Biochemical assessment of bone turnover and bone fragility in men

Authors: P. Szulc, J. M. Kaufman, P. D. Delmas

Published in: Osteoporosis International | Issue 11/2007

Abstract

Summary

Osteoporosis in men is less studied than in women. Few data concern biochemical bone turnover markers (BTM) in men and their potential use.

Methodology

We evaluated papers concerning BTM in men cited on Medline. Selection of studies were based on the number of subjects, age range, group homogeneity, follow-up duration, number of BTM.

Results

BTM levels are high in young men, then decrease with age.In elderly men, bone resorption increases with age more than bone formation. Variability of individual values is high and their significance is unclear. In elderly men, BTM levels correlate negatively with bone mineral density suggesting that accelerated bone turnover underlies age-related bone loss. Data on the prediction of accelerated bone loss and fractures by BTM in men are scant. Testosterone treatment induces a decrease in bone resorption followed by a decrease in bone formation. Bisphosphonates and calcitonin decrease BTM levels in osteoporotic men. Parathyroid hormone 1–34 and growth hormone induce a rapid increase in bone turnover followed by a progressive slowdown.

Conclusions

Few studies concern BTM in men. Currently available data are not sufficient to suggest guidelines for the practical use of BTM in the clinical management of the osteoporosis in elderly men.

Fransen M, Woodward M, Norton R, Robinson E, Butler M, Campbell AJ (2002) Excess mortality or institutionalisation after hip fracture: men are at greater risk than women. J Am Geriatr Soc 50:685–690PubMedCrossRef

Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J (2000) The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 11(Suppl 6):S2–S17PubMedCrossRef

Lieuw-a-Fa M, Sierra RI, Specker BL (1995) Carboxy-terminal propeptide of human type I collagen and pyridinium cross-links as markers of bone growth in infants 1 to 18 months of age. J Bone Miner Res 10:849–853PubMed

Tobiume H, Kanzaki S, Hida S, Ono T, Moriwake T, Yamauchi S et al (1997) Serum bone alkaline phosphatase isoenzyme levels in normal children and children with growth hormone (GH) deficiency : a potential marker for bone formation and response to GH therapy. J Clin Endocrinol Metab 82:2056–2061PubMedCrossRef

Marowska J, Kobylinska M, Lukaszewicz J, Talajko A, Rymkiewicz-Kluczynska B, Lorenc RS (1996) Pyridinium crosslinks of collagen as a marker of bone resorption rates in children and adolescents : normal values and clinical applications. Bone 19:669–677PubMedCrossRef

Mora S, Prinster C, Proverbio MC, Bellini A, de Poli SCL, Weber G et al (1998) Urinary markers of bone turnover in healthy children and adolescents : age-related changes and effect of puberty. Calcif Tissue Int 63:369–374PubMedCrossRef

Coeverden SCCM van, Netelenbos JC, de Ridder CM, Roos JC, Popp-Snijders C, Delemarre-van de Waal HA (2002) Bone metabolism markers and bone mass in healthy pubertal boys and girls. Clin Endocrinol 57:107–116CrossRef

Rauch F, Schönau E, Woitge H, Remer T, Seibel M (1994) Urinary excretion of hydroxy-pyridinium cross-links of collagen reflects skeletal growth velocity in normal children. Exp Clin Endocrinol 102:94–97PubMedCrossRef

Seeman E (2001) Sexual dimorphism in skeletal size, density and strength. J Clin Endocrinol Metab 86:4576–4584PubMedCrossRef

10.

Gundberg CM, Looker AC, Nieman SD, Calvo MS (2002) Patterns of osteocalcin and bone alkaline phosphatase by age, gender, and race or ethnicity. Bone 31:703–708PubMedCrossRef

11.

Szulc P, Garnero P, Munoz F, Marchand F, Delmas PD (2001) Cross-sectional evaluation of bone metabolism in men. J Bone Miner Res 16:1642–1650PubMedCrossRef

12.

Fatayerji D, Eastell R (1999) Age-related changes in bone turnover in men. J Bone Miner Res 14:1203–1210PubMedCrossRef

13.

Khosla S, Melton LJ III, Atkinson EJ, O’Fallon WM, Klee GG, Riggs BL (1998) Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 83:2266–2274PubMedCrossRef

14.

Wishart JM, Need AG, Horowitz M, Morris HA, Nordin BEC (1995) Effect of age on bone density and bone turnover in men. Clin Endocrinol 42:141–145

15.

Chandani AK, Scariano JK, Glew RH, Clemens JD, Garry PJ, Baumgartner RN (2000) Bone mineral density and serum levels of aminoterminal propeptides and cross-linked N-telopeptides of type I collagen in elderly men. Bone 26:513–518PubMedCrossRef

16.

Gallagher JC, Kinayamu HK, Fowler SE, Dawson-Hughes B, Dalsky GP, Sherman SS (1998) Calciotropic hormones and bone markers in the elderly. J Bone Miner Res 13:475–482PubMedCrossRef

17.

Wang X, Shen X, Li X, Mauli Agrawal C (2002) Age-related changes in the collagen network and toughness of bone. Bone 31:1–7PubMedCrossRef

18.

Minisola S, Dionisi S, Pacitti MT, Paglia F, Carnevale V, Scillitani A et al (2002) Gender differences in serum markers of bone resorption in healthy subjects and patients with disorders affecting bone. Osteoporos Int 13:171–175PubMedCrossRef

19.

Orwoll ES, Bell NH, Nanes MS, Flessland KA, Pettinger MB, Mallinak NJS, Cain DF (1998) Collagen N-telopeptide excretion in men : the effects of age and intrasubject variability. J Clin Endocrinol Metab 83:3930–3935PubMedCrossRef

20.

Colwell A, Eastell R (1996) Renal clearance of free and conjugated pyridinium crosslinks of collagen. J Bone Miner Res 11:1976–1980PubMed

21.

Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD (1995) Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 10:641–649PubMedCrossRef

22.

Falahati-Nini A, Riggs BL, Atkinson EJ, O’Fallon WM, Eastell R, Khosla S (2000) Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 106:1553–1560PubMedCrossRef

23.

Szulc P, Munoz F, Claustrat B, Garnero P, Marchand F, Duboeuf F, Delmas PD (2001) Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J Clin Endocrinol Metab 86:192–199PubMedCrossRef

24.

Lips P, Courpron P, Meunier PJ (1978) Mean wall thickness in trabecular bone packets in the human iliac crest: changes with age. Calcif Tissue Res 26:13–17PubMedCrossRef

25.

Grenspan SL, Dresner-Pollak R, Parker RA, London D, Fergusson L (1997) Diurnal variation of bone mineral turnover in elderly men and women. Calcif Tissue Int 60:419–423CrossRef

26.

Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C (2002) Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 31:57–61PubMedCrossRef

27.

Wichers M, Schmidt E, Bidlingmaier F, Klingmüller D (1999) Diurnal rhythm of crosslaps in human serum. Clin Chem 45:1858–1860PubMed

28.

Gundberg CM, Markowitz ME, Mizruchi M, Rosen JF (1985) Osteocalcin in human serum: a circadian rhythm. J Clin Endocrinol Metab 60:736–739PubMed

29.

Schlemmer A, Hassager C, Alexandersen P, Fledelius C, Pedersen BJ, Kristensen LO, Christiansen C (1997) Circadian variation in bone resorption is not related to serum cortisol. Bone 21:83–88PubMedCrossRef

30.

Ahmad AM, Hopkins MT, Fraser WD, Ooi CG, Durham BH, Vora JP (2003) Parathyroid hormone secretory pattern, circulating activity, and effect on bone turnover in adult hormone deficiency. Bone 32:170–179PubMedCrossRef

31.

Ledger GA, Burkitt MF, Kao PC, O’Fallon WM, Riggs BL, Khosla S (1995) Role of parathyroid hormone in mediating nocturnal and age-related increases in bone resorption. J Clin Endocrinol Metab 80:3304–3310PubMedCrossRef

32.

Henriksen DB, Alexandersen P, Bjarnason NH, Vilsboll T, Hartmann B, Henriksen EE et al (2003) Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 18:2180–2189PubMedCrossRef

33.

Szulc P, Marchand F, Duboeuf F, Delmas PD (2000) Cross-sectional assessment of age-related bone loss in men. Bone 26:123–129PubMedCrossRef

34.

Kenny AM, Gallagher JC, Prestwood KM, Gruman CA, Raisz LG (1998) Bone density, bone turnover, and hormone levels in men over age 75. J Gerontol Biol Sci Med Sci 53A:M419–M425

35.

Schneider DL, Barrett-Connor EL (1997) Urinary N-telopeptide levels discriminate normal, osteopenic and osteoporotic bone mineral density. Arch Intern Med 157:1241–1245PubMedCrossRef

36.

Szulc P, Delmas PD (2006) Bone turnover markers predict long term bone loss in elderly men – the prospective MINOS study. J Bone Miner Res 21 (Suppl 1) S109 Abstract F336

37.

Cheng S, Suominen H, Väänänen K, Käkönen SM, Pettersson K, Heikkinen E (2002) Serum osteocalcin in relation to calcaneal bone mineral density in elderly men and women: a 5-year follow-up. J Bone Miner Res 20:49–56CrossRef

38.

Scopacasa F, Wishart JM, Need AG, Horowitz M, Morris HA, Nordin BEC (2002) Bone density and bone-related biochemical variables in normal men: a longitudinal study. J Gerontol Med Sci Biol Sci 57A:M385–M391

39.

Goemaere SJA, Zmierczak H, van Pottelbergh I, Demuynck R, Myny H, Kaufman JM (2001) Association of bone turnover with longitudinally assessed bone loss in community-dwelling elderly men. J Bone Miner Res 16 (Suppl 1) S395 Abstract Su356

40.

Yoshimura N, Hashimoto T, Sakata K, Morioka S, Kasamatsu T, Cooper C. (1999) Biochemical markers of bone turnover and bone loss at the lumbar spine and femoral neck: the Taiji study. Calcif Tissue Int 65:198–202PubMedCrossRef

41.

Dennison E, Eastell R, Fall CHD, Kellingray S, Wood PJ, Cooper C (1999) Determinants of bone loss in elderly men and women: a prospective population-based study. Osteoporosis Int 10:384–391CrossRef

42.

Szulc P, Garnero P, Marchand F, Dubeouf F, Delmas PD (2005) Biochemical markers of bone formation reflect endosteal bone loss in elderly men - MINOS study. Bone 36:13–21PubMedCrossRef

43.

Luukinen H, Kakonen SM, Pettersson K, Koski K, Laippala P, Lovgren T et al (2000) Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin. J Bone Miner Res 15:2473–2478PubMedCrossRef

44.

Meier C, Nguyen TV, Center JR, Seibel MJ, Eisman JA (2005) Bone resorption and osteoporotic fractures in elderly men: the Dubbo osteoporosis epidemiology study. J Bone Miner Res 20:579–587PubMedCrossRef

45.

McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE et al (2004) Homocysteine as a predictive factor for hip fractures in elderly persons. N Engl J Med 350:2042–2049PubMedCrossRef

46.

Meurs JBJ van, Dhonukshe-Rutten RAM, Pluijm SMF, van der Klift M, de Jonge R, Lindemans J et al (2004) Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 350:2033–2041PubMedCrossRef

47.

Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K (2005) Homocysteine as a predictive factor for hip fracture in stroke patients. Bone 36:721–726PubMedCrossRef

48.

Dhonukshe-Rutten RAM, Pluijm SMF, de Groot LCPGM, Lips P, Smit JH, van Staveren WA (2005) Homocysteine and vitamin B12 status relate to bone turnover markers, broadband ultrasound attenuation, and fractures in healthy elderly people. J Bone Miner Res 20:921–929PubMedCrossRef

49.

Ravaglia G, Forti P, Maioli F, Servadei L, Martelli M, Brunetti N et al (2005) Folate, but not homocysteine, predicts the risk of fracture in elderly persons. J Gerontol Med Sci Biol Sci 60A:1458–1462

50.

Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE (1997) Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337:230–236PubMedCrossRef

51.

Raposo B, Rodriguez C, Martinez-Gonzalez J, Badimon L (2004) High levels of homocysteine inhibit lysyl oxidase (LOX) and downregulate LOX expression in vascular endothelial cells. Atherosclerosis 177:1–8PubMedCrossRef

52.

Herrmann M, Widmann T, Colaianni G, Colucci S, Zallone A, Herrmann W (2005) Increased osteoclast activity in the presence of increased homocysteine concentrations. Clin Chem 51:2348–2353PubMedCrossRef

53.

Khan M, Yamauchi M, Srisawasdi S, Stiner D, Doty S, Paschalis EP, Boskey AL (2001) Homocysteine decreases chondrocyte-mediated matric mineralization in differentiating chick limb-bud mesenchymal cell micro-mass cultures. Bone 28:387–398PubMedCrossRef

54.

Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM et al (2004) Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 89:503–510PubMedCrossRef

55.

Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ et al (2004) Long-term testosterone gel (Androgel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 89:2085–2098PubMedCrossRef

56.

Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G et al (2001) Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol 54:739–750CrossRef

57.

Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH et al (1999) Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84:1966–1972PubMedCrossRef

58.

Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG (2001) Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol Med Sci Biol Sci 56A:M266–M272

59.

Tenover JS (1992) Effects of testosterone supplementation in the aging male. J Clin Endcrinol Metab 75:1092–1098CrossRef

60.

Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A et al (2000) Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 85:2670–2677PubMedCrossRef

61.

Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292–299PubMedCrossRef

62.

Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Lann RF et al (2000) Effects or risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277–286PubMedCrossRef

63.

Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E et al (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids. Arthrit Rheum 44:202–211CrossRef

64.

Lems WF, Lodder MC, Lips P, Bijlsma JWJ, Geusens P, Schrameijer N et al (2006) Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatement with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Osteoporos Int 17:716–723PubMedCrossRef

65.

Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J et al (2000) Alendronate treatment of osteoporosis in men. N Engl J Med 343:604–610PubMedCrossRef

66.

Reid DM, Adami S, Devogelaer JP, Chines AA (2001) Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 69:242–247PubMedCrossRef

67.

Sato Y, Iwamoto J, Kanoko T, Satoh K (2005) Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 165:1743–1748PubMedCrossRef

68.

Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M et al (1999) Risedronate therapy prevents corticosteroid-induced bone loss. A twelve-month, multicenter, randomize, double-blind, placebo-controlled, parallel-group study. Arthrit Rheum 42:2309–2318CrossRef

69.

Stepan JJ, Burckhardt P, Hána V (2003) The effcts of three-month intravenous ibandronate on bone mineral density and bone remodeling in Klinefelter’s syndrome: the influence of vitamin D deficiency and hormonal status. Bone 33:589–596PubMedCrossRef

70.

Trovas GP, Lyritis GP, Galanos A, Raptou P, Constantelou EA (2002) A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res 17:521–527PubMedCrossRef

71.

Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A et al (2003) The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9–17PubMedCrossRef

72.

Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP (2000) Parathyroid hormone as a therapy for idiopathic osteoporosis in men : effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85:3069–3076PubMedCrossRef

73.

Finkelstein JS, Leder BZ, Burnett SA, Wyland JJ, Lee H, de la Paz AV et al (2006) Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 91:2882–2887PubMedCrossRef

74.

Delmas PD, Chatelain P, Malaval M, Bonne G (1986) Serum bone GLA-protein in growth hormone deficient children. J Bone Miner Res 1:333–338PubMed

75.

Bravenboer N, Holzmann PJ, ter Maaten JC, Stuurman LM, Roos JC, Lips P (2005) Effect of long-term growth hormone treatment on bone mass and bone metabolism in growth hormone-deficient men. J Bone Miner Res 20:1778–1784PubMedCrossRef

76.

Johansson AG, Lindh E, Blum WF, Kollerup G, Sorensen OH, Ljunghall S (1996) Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis. J Clin Endocrinol Metab 81:44–48PubMedCrossRef

77.

Ahmad AM, Thomas J, Clewes A, Hopkins MT, Guzder R, Ibrahim H et al (2003) Effects of growth hormone replacement on parathyroid hormone sensitivity and bone mineral metabolism. J Clin Endocrinol Metab 88:2860–2868PubMedCrossRef

78.

Gillberg P, Mallmin H, Petrén-Mallmin M, Ljunghall S, Nilsson AG (2002) Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis. J Clin Endocrinol Metab 87:4900–4906PubMedCrossRef

79.

Välimäki MJ, Salmela PI, Salmi J, Viikari J, Kataja M, Turunen H, Soppi E (1999) Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults. Eur J Endocrinol 149:545–554CrossRef

80.

Hansen TB, Brixen K, Vahl N, Lunde Jorgensen JO, Christiansen JS, Mosekilde L, Hagen C (1996) Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency : a double blind, randomized, placebo-controlled study. J Clin Endocrinol Metab 81:3352–3359PubMedCrossRef

81.

Christmas C, O’Connor KG, Harman SM, Tobin JD, Münzer T, Bellantoni MF et al (2002) Growth hormone and sex steroid effects on bone metabolism and bone mineral density in healthy aged women and men. J Gerontol Med Sci Biol Sci 57A:M12–M18

82.

Chen JS, Cameron ID, Cumming RG, Lord SR, March LM, Sambrook PN et al (2006) Effect of age-related chronic immobility on markers of bone turnover. J Bone Miner Res 21:324–331PubMedCrossRef

83.

Sambrook P, Chen C, March L, Cameron I, Cumming R, Simpson J, Seibel M (2006) High bone turnover is an independent predictor of mortality in frail elderly. J Bone Miner Res 21:549–555PubMedCrossRef

Title: Biochemical assessment of bone turnover and bone fragility in men
Authors: P. Szulc
J. M. Kaufman
P. D. Delmas
Publication date: 01-11-2007
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 11/2007
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-007-0407-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Biochemical assessment of bone turnover and bone fragility in men

Abstract

Summary

Methodology

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Methodology

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2007

Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland

Interferential and horizontal therapies in chronic low back pain due to multiple vertebral fractures: a randomized, double blind, clinical study

Precision and accuracy of measuring changes in bone mineral density by dual-energy X-ray absorptiometry

Hypovitaminosis D and secondary hyperparathyroidism in the elderly: risk factors for hip fracture or markers of frailty?

Device-specific thresholds to diagnose osteoporosis at the proximal femur: an approach to interpreting peripheral bone measurements in clinical practice: Reply to comment by Pluskiewicz and Drozdzowska

Complementary and alternative medicine use by osteoporosis clinic patients